The first one of these 120 potential biomarkers to highlight is HKa, a protein previously shown to be elevated in plasma of patients with HAE-C1INH and a pharmacodynamic biomarker of lanadelumab bioactivity (10–12). The gene discussed is SERPING1; the disease is hereditary angioedema.